SGLT2 inhibitors may help treat NAFLD/NASH by reducing insulin resistance and improving glucose control, thereby lowering hepatic fat accumulation and inflammation, although their exact mechanism in this context is still being studied. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.